Nasdaq · Healthcare
LENZ Therapeutics, Inc. (LENZ)
As-reported financials and recent SEC filings for LENZ Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$19.1M
Net income
$-82.1M
Net margin
—
Diluted EPS
$-2.85
ROE
-28.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-91.1M | $-58.6M | $-72.4M | $-105.6M | $-60.4M |
| Net income | $-82.1M | $-49.8M | $-70.0M | $-101.1M | $-70.8M |
| Diluted EPS | $-2.85 | $-2.34 | $-3.25 | $-4.68 | $-6.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-02
View on EDGAR →SCHEDULE 13G2026-06-26
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Largest Healthcare peers
Go deeper on LENZ
Search LENZ Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.